PDC*line Pharma CMO and CSO will be present at ESMO Immuno Oncology Congress in Geneva, Switzerland – 07 Dec – 10 Dec 2017. A poster will be presented describing our last results with Neo-Antigens. Title of the abstract is: “PDC*vac: a powerful platform for priming and expanding Neo-Antigen specific-T cells”.

There is a paradigm shift in the treatment of cancer with recent research demonstrating that the immune system has tremendous potential to destroy tumours. Is immuno-oncology the new era of cancer medicine?